TNFSF11 and non-small cell lung carcinoma: A recent phase 1B/2 trial in non-small cell lung cancer (NSCLC) studied the effects of nivolumab, an anti-PD-1 inhibitor, combined with denosumab, a monoclonal antibody inhibiting receptor activator of NF-κB ligand (RANKL).